Posts tagged Future

dynamics of health care financing in Europe is changing. As governments review their options for responding to requests for health care is increasingly limited resources, the possibility of combining cost reduction with new sources of funding support in many countries to win. Decisions on reimbursement in the public sector are more difficult for pharmaceutical manufacturers and diagnosis in the private market offers a potential alternative route to market access.
private insurers currently play different roles in the European national health systems. This report examines their role in key European markets and provides an overview of trends in the coverage of health services and products. There are some areas where private insurance products could fill gaps in the refund. A survey of the private insurance industry in Europe, including the general trends and profiles of leading insurers and provides an indication of future developments in the industry, offering opportunities for pharmaceutical and diagnostic work with private insurers.

main features of this report

• Health systems and reviews the role of private insurers in the five main European markets of France, Germany, Italy, Spain and the United Kingdom.
• Analyze the health systems in the Netherlands and Switzerland, where the insurance from private insurers, which is purchased in regulated competing models. These have parallels with the system state of Massachusetts, who was a model for other states and the federal reform.
• Consider some of the problems in obtaining market access for pharmaceuticals and diagnostics through coverage by private health insurers and underlines the initiatives taken by the insurer, the possibilities of a partnership have made for businesses.
• Information on trends in private health insurance market, including the relative market shares of major markets in terms of benefits paid by private insurers.

scope of the report

• Understand the different roles played by private insurance in the financing of pharmaceutical and diagnostic products in key European markets and the relative importance of private funding of health expenditure.
• Identify key players in each market that are potential targets for market access to be financed privately.
• Revisit what new possibilities could in the private sector for products that are denied reimbursement will be offered in the public sector.
• The product portfolio tailored to meet the different needs of different markets.

key market issues

• The role of private health insurance depends on the coverage by the National Health Service provided. Do you understand what type of private health insurance – Alternative / primary, complementary / supplementary or dual / Competition – is dominant in any market is essential for assessing the market potential.
• For reimbursement of medical diagnosis and treatment in the public sector is becoming increasingly difficult in many countries such as cost and medical necessity of certain products are subject to further review by public borrowers. Some private insurance companies show interest in drug coverage for minor ailments and lifestyle products that are excluded from government reimbursement.
• Cost management is a challenge for the private insurers in the current economic situation of medical inflation and price competition in the industry to create additional pressure. Insurers adjust their portfolios to meet the market, with an emphasis on prevention and promoting healthy lifestyles.

main findings of this report

• More than 84 million Europeans are suffering from some form of private health insurance. Germans make up the largest proportion of the population with private insurance, with 22.3 million, followed by the Netherlands with 16.2 million euros.
• health services by private insurers account for 8% of total health spending in Europe, an action that increase to define the path as a public pay their benefits will be paid.
• The cost of drugs is an important part of the costs of private insurers in most markets. Approximately 93% of the French population has no insurance to cover the costs paid health insurance, with 30% of the costs for insurers, the cost of drugs.
• Private insurers provide comprehensive health insurance to 10.5% of Germans and almost the entire population of the Netherlands and Switzerland. Voluntary insurance plays an important role in these markets to support and complement all the legal benefits
• France has the highest density of private health insurance to 893, while the industry is relatively concentrated among the actors low in most other markets. – There are 46 insurance companies in Germany, 30 in the Netherlands and 27 in the United Kingdom.

answers important questions />

• How many Europeans have private health insurance and why they buy private insurance?
• What proportion of health spending by private insurers in key European markets to be paid?
• How are influenced by a private insurance reimbursement decisions of public health medicine?
• Who are the actors and influence in the European market for private health insurance?
• What are the current activities of the insurers are to cover the medicines are not reimbursed national health systems?
• What is the role of private insurers play in public-private partnerships?

Contact:

Vision Shop Planters
Tel: 91-22 -40583000
EMAILID: marketing@visionshopsters.com Site
: www.visionshopsters.com

The World Health